
    
      The study will consist of two parts: Subjects will be randomized to receive SHR-1707 as
      reflected by the guiding principle for the dose esclation/expansion phase. Each dose group
      includes a screening period, a baseline period, an observational period, and a safety
      follow-up period.
    
  